Reich K, et al. - Among patients (aged 18 years or older) with moderate-to-severe chronic plaque psoriasis enrolled in IMMvent, risankizumab was compared to adalimumab in terms of efficacy and safety. This study was done in two parts, part A and part B. In a random manner 1:1, patients were allocated to 150 mg risankizumab subcutaneously at weeks 0 and 4 or 80 mg adalimumab subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter during a 16-week double-blind treatment period (part A). Re-randomization 1:1 of adalimumab intermediate responders to continue 40 mg adalimumab or switch to 150 mg risankizumab was done for weeks 16–44 (part B). Compared to adalimumab, significantly greater efficacy of risankizumab for providing skin clearance was evident in this study. For patients who switched from adalimumab to risankizumab, there were no additional safety issues. In the long-term treatment of psoriasis, flexibility is offered by risankizumab use.